Journal
CLINICAL CANCER RESEARCH
Volume 18, Issue 17, Pages 4682-4690Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-3260
Keywords
-
Categories
Funding
- German Ministry of Science and Education (BMBF) [01GS08100]
- Max Planck Society [NEUR8061]
- Deutsche Forschungsgemeinschaft (DFG) [SFB832]
- EU [HEALTH-F2-2010-258677]
- Behrens-Weise Foundation
- anonymous foundation
- VICC Cancer Center Core grant [P30-CA68485]
- Research Excellence in Lung Cancer grant [CA90949]
- NIH [5T32 CA119910-04]
- Uniting Against Lung Cancer grant
- ASCO YIA
- AstraZeneca
- Enzon
- Symphogen
- Xcovery
- Merck
- EOS
Ask authors/readers for more resources
Purpose: ALK rearrangement-positive lung cancers can be effectively treated with ALK inhibitors. However, the magnitude and duration of response is heterogeneous. In addition, acquired resistance limits the efficacy of ALK inhibitors, with most upfront resistance mechanisms being unknown. Experimental Design: By making use of the Ba/F3 cell line model, we analyzed the cytotoxic efficacy of ALK kinase inhibitors as a function of different EML4-ALK fusion variants v1, v2, v3a, and v3b as well as of three artificially designed EML4-ALK deletion constructs and the ALK fusion genes KIF5b-ALK and NPM1-ALK. In addition, the intracellular localization, the sensitivity to HSP90 inhibition and the protein stability of ALK fusion proteins were studied. Results: Different ALK fusion genes and EML4-ALK variants exhibited differential sensitivity to the structurally diverse ALK kinase inhibitors crizotinib and TAE684. In addition, differential sensitivity correlated with differences in protein stability in EML4-ALK-expressing cells. Furthermore, the sensitivity to HSP90 inhibition also varied depending on the ALK fusion partner but differed from ALK inhibitor sensitivity patterns. Finally, combining inhibitors of ALK and HSP90 resulted in synergistic cytotoxicity. Conclusions: Our results might explain some of the heterogeneous responses of ALK-positive tumors to ALK kinase inhibition observed in the clinic. Thus, targeted therapy of ALK-positive lung cancer should take into account the precise ALK genotype. Furthermore, combining ALK and HSP90 inhibitors might enhance tumor shrinkage in EML4-ALK-driven tumors. Clin Cancer Res; 18(17); 4682-90. (C)2012 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available